Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.
Animals
Animals, Genetically Modified
Aortic Diseases
/ genetics
Apolipoprotein C-III
/ deficiency
Atherosclerosis
/ genetics
Biomarkers
/ blood
Cholesterol, HDL
/ blood
Cholesterol, VLDL
/ blood
Coronary Artery Disease
/ genetics
Disease Models, Animal
Female
Hep G2 Cells
Hepatocytes
/ metabolism
Humans
Lipoproteins, IDL
/ blood
Liver
/ metabolism
Male
Oxidation-Reduction
Plaque, Atherosclerotic
Rabbits
Triglycerides
/ blood
aorta
apolipoprotein CIII
atherosclerosis
hyperlipidemias
lipoproteins
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
8
8
2020
medline:
8
10
2020
entrez:
8
8
2020
Statut:
ppublish
Résumé
Apo (apolipoprotein) CIII mediates the metabolism of triglyceride (TG)-rich lipoproteins. High levels of plasma apoCIII are positively correlated with the plasma TG levels and increase the cardiovascular risk. However, whether apoCIII is directly involved in the development of atherosclerosis has not been fully elucidated. Approach and Results: To examine the possible roles of apoCIII in lipoprotein metabolism and atherosclerosis, we generated apoCIII KO (knockout) rabbits using ZFN (zinc finger nuclease) technique. On a normal standard diet, apoCIII KO rabbits exhibited significantly lower plasma levels of TG than those of WT (wild type) rabbits while total cholesterol and HDL (high-density lipoprotein) cholesterol levels were unchanged. Analysis of lipoproteins isolated by sequential ultracentrifugation revealed that reduced plasma TG levels in KO rabbits were accompanied by prominent reduction of VLDLs (very-low-density lipoproteins) and IDLs (intermediate-density lipoproteins). In addition, KO rabbits showed faster TG clearance rate after intravenous fat load than WT rabbits. On a cholesterol-rich diet, KO rabbits exhibited constantly and significantly lower levels of plasma total cholesterol and TG than WT rabbits, which was caused by a remarkable reduction of β-VLDLs-the major atherogenic lipoproteins. β-VLDLs of KO rabbits showed higher uptake by cultured hepatocytes and were cleared faster from the circulation than β-VLDLs isolated from WT rabbits. Both aortic and coronary atherosclerosis was significantly reduced in KO rabbits compared with WT rabbits. These results indicate that apoCIII deficiency facilitates TG-rich lipoprotein catabolism, and therapeutic inhibition of apoCIII expression may become a novel means not only for the treatment of hyperlipidemia but also for atherosclerosis.
Identifiants
pubmed: 32757647
doi: 10.1161/ATVBAHA.120.314368
pmc: PMC7484272
mid: NIHMS1614628
doi:
Substances chimiques
Apolipoprotein C-III
0
Biomarkers
0
Cholesterol, HDL
0
Cholesterol, VLDL
0
Lipoproteins, IDL
0
Triglycerides
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2095-2107Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL117491
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129778
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL147527
Pays : United States
Références
J Clin Invest. 1985 Feb;75(2):384-90
pubmed: 3973011
Eur Heart J. 2019 Sep 1;40(33):2785-2796
pubmed: 31329855
Nutr Metab Cardiovasc Dis. 2012 Jan;22(1):1-7
pubmed: 22176921
J Clin Invest. 1998 May 15;101(10):2151-64
pubmed: 9593771
Curr Opin Lipidol. 2018 Jun;29(3):171-179
pubmed: 29547399
J Clin Endocrinol Metab. 2004 Aug;89(8):3949-55
pubmed: 15292332
Circulation. 2009 Nov 24;120(21):2088-94
pubmed: 19901190
Cardiol Clin. 2018 May;36(2):265-275
pubmed: 29609756
Pharmacol Ther. 2015 Feb;146:104-19
pubmed: 25277507
J Lipid Res. 2010 Jan;51(1):150-61
pubmed: 19622837
J Clin Invest. 1986 Nov;78(5):1287-95
pubmed: 3095375
Circulation. 2006 Feb 7;113(5):691-700
pubmed: 16461842
Biochim Biophys Acta. 1978 Jun 15;541(2):234-40
pubmed: 208636
Science. 2008 Dec 12;322(5908):1702-5
pubmed: 19074352
Nat Med. 2017 Sep;23(9):1086-1094
pubmed: 28825717
Circulation. 2006 Aug 15;114(7):681-7
pubmed: 16894036
Clin Chim Acta. 2018 Dec;487:54-59
pubmed: 30218657
J Biol Chem. 1996 Jan 19;271(3):1776-83
pubmed: 8576182
J Clin Invest. 1992 Nov;90(5):1889-900
pubmed: 1430212
N Engl J Med. 2015 Jul 30;373(5):438-47
pubmed: 26222559
J Atheroscler Thromb. 2018 Mar 1;25(3):213-220
pubmed: 29046488
Transgenic Res. 2011 Aug;20(4):867-75
pubmed: 21120692
Cardiovasc Res. 2015 Sep 1;107(4):579-89
pubmed: 26160324
J Lipid Res. 1985 May;26(5):556-65
pubmed: 4020294
J Biol Chem. 2011 Aug 5;286(31):27769-80
pubmed: 21676879
Science. 1990 Aug 17;249(4970):790-3
pubmed: 2167514
Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):239-45
pubmed: 19910636
Circulation. 2010 Apr 20;121(15):1722-34
pubmed: 20368524
J Lipid Res. 2001 Oct;42(10):1578-85
pubmed: 11590213
Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):963-71
pubmed: 7600129
Proc Natl Acad Sci U S A. 1983 Oct;80(19):6096-100
pubmed: 6577469
J Clin Invest. 1995 Feb;95(2):705-12
pubmed: 7860752
Science. 1997 Jan 17;275(5298):391-4
pubmed: 8994037
J Biol Chem. 1969 Oct 25;244(20):5687-94
pubmed: 4981584
Arteriosclerosis. 1981 May-Jun;1(3):177-85
pubmed: 6895305
N Engl J Med. 2014 Dec 4;371(23):2200-6
pubmed: 25470695
Circ Res. 2013 May 24;112(11):1479-90
pubmed: 23542898
Arteriosclerosis. 1988 Sep-Oct;8(5):471-9
pubmed: 3190554
Arterioscler Thromb Vasc Biol. 2016 May;36(5):810-816
pubmed: 26988589
N Engl J Med. 2014 Jul 3;371(1):22-31
pubmed: 24941081
J Clin Invest. 2016 Aug 1;126(8):2855-66
pubmed: 27400128
Cardiovasc Hematol Disord Drug Targets. 2012 Dec;12(2):133-40
pubmed: 23030451
J Biol Chem. 1994 May 6;269(18):13429-36
pubmed: 8175774
Lab Invest. 2004 Jun;84(6):715-26
pubmed: 15122303
Circ Res. 2013 May 24;112(11):1405-8
pubmed: 23704213
N Engl J Med. 2014 Jul 3;371(1):32-41
pubmed: 24941082
J Vis Exp. 2013 Nov 18;(81):e50957
pubmed: 24301055
Biochem Biophys Res Commun. 1972 Jan 31;46(2):375-82
pubmed: 5057882
J Lipid Res. 1993 Feb;34(2):325-30
pubmed: 8381454
J Biol Chem. 2001 Oct 26;276(43):40071-9
pubmed: 11477088
J Biol Chem. 1994 Sep 23;269(38):23610-6
pubmed: 8089130
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2047-53
pubmed: 19778946
Diabetes. 2009 Sep;58(9):2018-26
pubmed: 19502413
J Clin Invest. 1997 Jun 1;99(11):2672-81
pubmed: 9169497
J Atheroscler Thromb. 2020 May 23;:
pubmed: 32448826
Am J Pathol. 2018 Dec;188(12):2936-2947
pubmed: 30248339
N Engl J Med. 2019 Aug 8;381(6):531-542
pubmed: 31390500
J Biol Chem. 1994 Jan 21;269(3):2324-35
pubmed: 8294490
Nature. 2017 Apr 12;544(7649):235-239
pubmed: 28406212
Trends Pharmacol Sci. 2015 Oct;36(10):675-687
pubmed: 26435212
Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1282-1289
pubmed: 28546217
J Lipid Res. 1996 Jan;37(1):210-20
pubmed: 8820116
J Biol Chem. 1974 Aug 10;249(15):4975-84
pubmed: 4846755